#ECTRIMS2021: EBV as a therapeutic target
https://multiple-sclerosis-research.org ... us-effect/
Conclusions: Preliminary data indicate ATA188 is well tolerated. Sustained EDSS improvement drove SDI in most pts, and in all but 1 pt, SDI was maintained at all subsequent timepoints. As a biomarker associated with disability, pts with sustained EDSS improvement (vs those without) showed greater increases in MTR signal at 12m, which may be suggestive of remyelination. The Phase 2 portion of this study, EMBOLD (NCT03283826), is ongoing and currently enrolling.
Antiviral therapy targeting EBV. Seems to work!!
Re: Antiviral therapy targeting EBV. Seems to work!!
Gavin Giovannoni wrote: “We are talking with Moderna but their EBV vaccine is behind their CMV vaccine in priority and it needs to be tested in phase 1 first.”
Comment: BioNTech is already working on an MS vaccine. Perhaps they would prioritize work on a EBC vaccine.
Comment: BioNTech is already working on an MS vaccine. Perhaps they would prioritize work on a EBC vaccine.
-
- Similar Topics
- Replies
- Views
- Last post
-
- 0 Replies
- 2168 Views
-
Last post by frodo
-
- 0 Replies
- 818 Views
-
Last post by frodo
-
- 0 Replies
- 1560 Views
-
Last post by frodo
-
- 0 Replies
- 1841 Views
-
Last post by Petr75
-
- 0 Replies
- 1219 Views
-
Last post by NHE
-
- 0 Replies
- 10799 Views
-
Last post by NHE
-
- 0 Replies
- 2507 Views
-
Last post by frodo
-
- 0 Replies
- 2655 Views
-
Last post by NHE
-
- 1 Replies
- 1867 Views
-
Last post by frodo